SEATTLE, WA, June 21, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today
announced the promotion of Scott Peterson, Ph.D., to Chief Scientific
Officer. Dr. Peterson joined Oncothyreon in August 2009 as Vice
President, Clinical Development.
"This promotion recognizes Scott's key role in advancing the scientific
and preclinical support for both PX-866, our
phosphatidylinositol-3-kinase (PI-3K) inhibitor currently in multiple
Phase 2 clinical trials, and ONT-10, our therapeutic vaccine targeting
MUC-1 currently in a Phase 1 clinical trial," said Robert L. Kirkman,
M.D, President and Chief Executive Officer. "He also leads the
scientific effort to expand this clinical pipeline, including the
ongoing preclinical development of ONT-701, our inhibitor of the Bcl-2
family of anti-apoptotic proteins."
Prior to joining Oncothyreon, Dr. Peterson was Director of Oncology
Research at ZymoGenetics Inc from 2007-2009. Prior to that, Dr.
Peterson was a Principal Scientist at ICOS Corporation where he led
both small molecule and antibody cancer drug discovery programs. Dr.
Peterson has a Ph.D. in Chemistry from the University of Colorado,
Boulder and a B.S. in Biology from Washington State University.
Oncothyreon is a biotechnology company specializing in the development
of innovative therapeutic products for the treatment of cancer.
Oncothyreon's goal is to develop and commercialize novel synthetic
vaccines and targeted small molecules that have the potential to
improve the lives and outcomes of cancer patients. For more
information, visit www.oncothyreon.com.
SOURCE Oncothyreon Inc.